final results from the phase 2 summit basket trial: targeting her2 advanced btcs with neratinib
Published 2 years ago • 50 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
2:49
neratinib, trastuzumab fulvestrant for her2-mutant, hr , metastatic breast cancer
-
4:52
neratinib fulvestrant trastuzumab for hr her2-mutant mbc and neratinib trastuzumab for tr...
-
1:51
eleanor interim analysis: real-world study of adjuvant neratinib in her2 /hr early breast cancer
-
2:35
dr. burris on updated monaleesa-2 trial results for hr breast cancer
-
21:00
gs4 10 neratinib fulvestrant trastuzumab for hormone receptor-positive, her2-mutant metastatic
-
56:27
ccf webinar: a clinical trial for a potential new ther2apy for biliary tract cancers
-
17:45
ask dr. murphy: rising us covid deaths, declining cardiovascular event rates, and more (08/09/2024)
-
1:01:34
er breast cancer case panel discussion | 2022 best of breast conference
-
3:09
overall survival results from monaleesa-3 study on ribociclib plus fulvestrant in advanced breas...
-
4:05
immunic ceo discusses q2 results & ms trials update
-
7:42
results from the aphinity trial of two her2 targeted agents with chemo
-
7:37
zanidatamab for her2-amplified, unresectable, locally advanced or metastatic biliary tract cancer
-
0:53
eleanor: real-world study of extended adjuvant neratinib in her2 /hr early breast cancer
-
36:45
decoding her2 in nsclc: advances in biomarker testing and targeted therapies
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
1:57
monarcher: final os results of abemaciclib in hr , her breast cancer
-
0:56
revolutionizing her2-positive breast cancer treatment: unveiling breakthrough results!
-
3:46
aphinity: 6-year follow-up results of dual her2 blockade in her2 breast cancer
-
4:37
neratinib-based combination therapy in her2-mutant lung cancer
-
10:15
monaleesa-3 os results: fulvestrant/ribociclib in postmenopausal hr /her2- advanced breast cancer
-
3:46
harmonia clinical trial
-
3:25
role for neratinib following adjuvant dual-targeted her2 therapy